Nintedanib plus best supportive care (BSC) versus placebo plus BSC for the treatment of patients (pts) with colorectal cancer (CRC) refractory to standard therapies: Results of the phase III LUME-colon 1 study

被引：2

作者：

Van Cutsem, E. ^{[1
]}

Yoshino, T. ^{[2
]}

Lenz, H-J. ^{[3
]}

Lonardi, S. ^{[4
]}

Falcone, A. ^{[5
]}

Limon, M. L. ^{[6
]}

Saunders, M. P. ^{[7
]}

Sobrero, A. ^{[8
]}

Maiello, E. ^{[9
]}

Park, Y. S. ^{[10
]}

Ferreiro Monteagudo, R. ^{[11
]}

Hong, Y. S. ^{[12
]}

Tomasek, J. ^{[13
]}

Taniguchi, H. ^{[14
]}

Ciardiello, F. ^{[15
]}

Hocke, J. ^{[16
]}

Oum'hamed, Z. ^{[17
]}

Vlassak, S. ^{[18
]}

Studeny, M. ^{[19
]}

Tabernero, J. ^{[20
]}

机构：

[1] Univ Hosp Leuven, Digest Oncol, Campus Gasthuisberg, Leuven, Belgium

[2] Natl Canc Ctr Hosp East, Dept GI Oncol, Kashiwa, Chiba, Japan

[3] Univ Southern Calif, Norris Comprehens Canc Ctr, Dept Med Oncol, Los Angeles, CA USA

[4] Ist Oncol Veneto IRCCS, Oncol Med 1, Padua, Italy

[5] Azienda Osped Univ S Chiara, Oncol Med, Pisa, Italy

[6] Hosp Univ Virgen del Rocio, Med Oncol, Seville, Spain

[7] Christie NHS Fdn Trust, Clin Oncol, Manchester, Lancs, England

[8] Osped San Martino Genova, Dept Med Oncol, Genoa, Italy

[9] Osped Casa Sollievo Sofferenza, Oncohematol, San Giovanni Rotondo, Italy

[10] Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Med, Seoul, South Korea

[11] Hosp Univ Ramon y Cajal, Med Oncol, Madrid, Spain

[12] Univ Ulsan, Coll Med, Asan Med Ctr, Oncol, Seoul, South Korea

[13] InVentiv Hlth, Med Commun, London, England

[14] Aichi Canc Ctr Hosp, Dept Clin Oncol, Nagoya, Aichi, Japan

[15] AOU SUN, Med Oncol, Naples, Italy

[16] Boehringer Ingelheim Pharma GmbH & Co KG, Stat, Tubingen, Germany

[17] Boehringer Ingelheim BV France SAS, Clin Trials, Reims, France

[18] SCS Boehringer Ingelheim Comm V, Med Affairs, Brussels, Belgium

[19] Boehringer Ingelheim GmbH & Co KG, Div Med, Clin Dev Dept, Vienna, Austria

[20] Vall dHebron Univ Hosp, Inst Oncol, Oncol Med, Barcelona, Spain

来源：

ANNALS OF ONCOLOGY | 2016年 / 27卷

关键词：

D O I：

10.1093/annonc/mdw435.12

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

LBA20_PR

引用

页数：1

共 50 条

[41] Subgroup Analysis of LUX-Lung 1: A Randomized Phase III Trial of Afatinib (BIBW 2992) + Best Supportive Care (BSC) versus Placebo plus BSC in Patients with NSCLC Failing 1-2 Lines of Chemotherapy and Erlotinib or Gefitinib
Miller, V. A.
Hirsch, V.
Cadranel, J.
Chen, Y.
Park, K.
Kim, S.
Lorence, R.
Shaidi, M.
Cong, J.
Yang, C.
JOURNAL OF THORACIC ONCOLOGY, 2010, 5 (12) : S557 - S558
[42] The influence of hypomagnesemia (hMg) on overall survival (OS) in a phase III randomized study of cetuximab (CET) plus best supportive care (BSC) versus BSC: NCIC CTG/AGITG CO.17
Vickers, M. M.
Karapetis, C. S.
Tu, D.
O'Callaghan, C. J.
Price, T. J.
Tebbutt, N. C.
Van Hazel, G.
Shapiro, J. D.
Pavlakis, N.
Gibbs, P.
Blondal, J.
Lee, U. J. Yu Min
Meharchand, J. M.
Burkes, R. L.
Rubin, S. H.
Simes, J.
Zalcberg, J. R.
Moore, M. J.
Zhu, L.
Jonker, D. J.
JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
[43] COST-EFFECTIVENESS OF PANITUMUMAB PLUS BEST SUPPORTIVE CARE (BSC) COMPARED WITH BSC ALONE IN CHEMOREFRACTORY METASTATIC COLORECTAL CANCER (MCRC) PATIENTS (PTS) WITH WILD-TYPE (WT) KRAS TUMOR STATUS IN THE NETHERLANDS
Graham, C. N.
Borker, R.
Oppe, M.
Groot, C. A. Uyl-de
Barber, B.
Brogan, A. J.
Amado, R. G.
Peeters, M.
Devercelli, G.
ANNALS OF ONCOLOGY, 2008, 19 : 134 - 134
[44] Phase III randomized study of second line ADI-PEG 20 plus best supportive care versus placebo plus best supportive care in patients with advanced hepatocellular carcinoma
Abou-Alfa, G. K.
Qin, S.
Ryoo, B-Y.
Lu, S-N.
Yen, C-J.
Feng, Y-H.
Lim, H. Y.
Izzo, F.
Colombo, M.
Sarker, D.
Bolondi, L.
Vaccaro, G.
Harris, W. P.
Chen, Z.
Hubner, R. A.
Meyer, T.
Sun, W.
Harding, J. J.
Hollywood, E. M.
Ma, J.
Wan, P. J.
Ly, M.
Bomalaski, J.
Johnston, A.
Lin, C-C.
Chao, Y.
Chen, L-T.
ANNALS OF ONCOLOGY, 2018, 29 (06) : 1402 - 1408
[45] A multicenter, randomized phase III trial comparing second-line chemotherapy (SLC) plus best supportive care (BSC) with BSC alone for pretreated advanced gastric cancer (AGC)
Park, S. H.
Lim, D. H.
Park, K.
Lee, S.
Oh, S. Y.
Kwon, H.
Kang, J. H.
Hwang, I. G.
Lee, J.
Park, J. O.
Park, Y. S.
Lim, H. Y.
Kang, W. K.
JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
[46] Best supportive care (BSC) versus oxaliplatin, folinic acid and 5-fluorouracil (OFF) plus BSC in patients for second-line advanced pancreatic cancer: A phase III-study from the German CONKO-study group
Pelzer, Uwe
Schwaner, Ingo
Stieler, Jens
Adler, Mathias
Seraphin, Joerg
Doerken, Bernd
Riess, Hanna
Oettle, Helmut
EUROPEAN JOURNAL OF CANCER, 2011, 47 (11) : 1676 - 1681
[47] Quality-adjusted time without symptoms of disease or toxicity (Q-TWiST) analysis of fruquintinib plus best supportive care (BSC) compared with placebo plus BSC in metastatic colorectal cancer (mCRC): Results from the FRESCO-2 trial
Stintzing, Sebastian
Tabernero, Josep
Satoh, Taroh
Dasari, Arvind
Lonardi, Sara
Eng, Cathy
Garcia-Carbonero, Rocio
Elez, Elena
Yoshino, Takayuki
Sobrero, Alberto F.
Yao, James C.
Kasper, Stefan
Arnold, Dirk
Basic, Edin
Granold, Matthias
Petschulies, Marco
Wu, Liwen
Chen, Lucy F.
Yang, Zhao
Van Cutsem, Eric
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
[48] Quality-adjusted time without symptoms of disease or toxicity (Q-TWiST) analysis of fruquintinib plus best supportive care (BSC) compared with placebo plus BSC in metastatic colorectal cancer (mCRC): Results from the FRESCO-2 trial
Stintzing, Sebastian
Tabernero, Josep
Satoh, Taroh
Dasari, Arvind
Lonardi, Sara
Eng, Cathy
Garcia-Carbonero, Rocio
Elez, Elena
Yoshino, Takayuki
Sobrero, Alberto F.
Yao, James C.
Kasper, Stefan
Arnold, Dirk
Basic, Edin
Granold, Matthias
Petschulies, Marco
Wu, Liwen
Chen, Lucy
Yang, Zhao
Van Cutsem, Eric
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (3_SUPPL) : 116 - 116
[49] Phase II randomized trial of autologous tumor lysate dendritic cell vaccine (ADC) plus best supportive care (BSC) compared with BSC, in pre-treated advanced colorectal cancer patients.
Maurel, Joan
Caballero-Baos, Miguel
Mila, Jordi
Tabera, Jaime
Varea, Sara
Vilana, Ramon
Bianchi, Luis
Arguis, Pedro
Pineda, Estela
Carrera, Gemma
Cuatrecasas, Miriam
Paez, David
Martin-Richard, Marta
Pages, Mario
Ramon Ayuso, Juan
Cid, Joan
Lozano, Miguel
Garcia-Albeniz, Xabier
Castells, Antoni
Vilella, Ramon
JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
[50] Final results from a phase III trial evaluating panitumumab (pmab) plus best supportive care (BSC) vs BSC in chemorefractory wild-type (WT) KRAS exon 2 and WT RAS metastatic colorectal cancer (mCRC).
Kim, Tae Won
Elme, Anneli
Kusic, Zvonko
Park, Joon Oh
Udrea, Anghel Adrian
Kim, Sun Young
Ahn, Joong Bae
Valencia, Ricardo Villalobos
Srinivasan, Krishnan
Bilic, Ante
Manojlovic, Nebojsa
Dong, Jun
Guan, Xuesong
Lofton-Day, Catherine
Jung, A. Scott
Vrdoljak, Eduard
JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)

← 1 2 3 4 5 →